https://www.selleckchem.com/pr....oducts/relacorilant.
d by the patient/donor disparities and alloantibody frequencies in different populations.We propose a class of alternative estimates and tests to restricted mean survival time (RMST) which improves power in numerous survival scenarios while maintaining a level of interpretability. The industry standards for interpretable hypothesis tests in survival analysis, RMST and logrank tests (LRTs), can suffer from low power in cases where the proportional hazards assumption fails. In particular, when late differences occur between survival
Curtir
Comentario
Compartilhar
